// Real-Time Intelligence Feed

Financial Intelligence.
Real-Time.

SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.

22,614
Stories Indexed
Live
Feed Status
6
Data Sources
LATEST
AllEarningsFDAM&AInsider TradingRegulatoryOfferingLeadershipRestructuringDividendInstitutional HoldingsBankruptcy
FDA · 22,614 results Live
FDA Aurobindo Apr 6 — 0.00

FDA Approves DAPAGLIFLOZIN — Aurobindo Pharma Limited

Aurobindo Pharma Limited announced the approval of its ANDA for dapagliflozin, granting it rights to manufacture and market this generic oral product by April 2026. This authorizat…

FDA Baxter Apr 3 — 0.00

FDA Approves PHENYLEPHRINE HYDROCHLORIDE — Baxter Healthcare Corporation

# FDA Approves Baxter Healthcare's Generic Phenylephrine Hydrochloride Injection Baxter Healthcare Corporation has received FDA approval for its generic phenylephrine hydrochlorid…

FDA Sandoz Apr 2 — 0.00

FDA Approves NINTEDANIB — Sandoz Inc

# FDA Approves Sandoz's Generic Nintedanib, Expanding Competition in Pulmonary Fibrosis Market Sandoz Inc. has received FDA approval for its generic nintedanib esylate oral formul…

FDA Dr. Apr 2 — 0.00

FDA Approves NINTEDANIB — Dr. Reddy's Laboratories Inc.

# FDA Approves Dr. Reddy's Laboratories' Generic Nintedanib Dr. Reddy's Laboratories Inc. received FDA approval for its generic nintedanib esylate oral formulation (ANDA219283), m…

FDA Apotex Apr 2 — 0.00

FDA Approves NINTEDANIB — Apotex Corp.

# FDA Approves Generic Version of Nintedanib, Enabling Significant Cost Savings for Pulmonary Fibrosis Patients Apotex Corp. has received FDA approval for a generic formulation of…

FDA EXELAN Apr 2 — 0.00

FDA Approves NINTEDANIB CAPSULES, 100 MG AND 150 MG — EXELAN PHARMACEUTICALS INC.

# FDA Approves Generic Nintedanib Capsules; Exelan Pharmaceuticals Enters Competitive Pulmonary Fibrosis Market Exelan Pharmaceuticals Inc. has received FDA approval for generic n…

FDA Edenbridge Apr 2 — 0.00

FDA Approves NINTEDANIB — Edenbridge Pharmaceuticals LLC.

Edenbridge Pharmaceuticals LLC has received FDA approval for its ANDA219819 application for Nintedanib Esyslate tablets, strengthening the firm’s portfolio with the generic version…

FDA Eli Apr 1 — 0.00

FDA Approves FOUNDAYO — Eli Lilly and Company

# FDA Approves Eli Lilly's FOUNDAYO for Oral Administration Eli Lilly and Company received FDA approval for FOUNDAYO (orforglipron calcium), an oral medication that expands the co…

FDA KLM Mar 31 — 0.00

FDA Approves MESALAMINE — KLM Laboratories Private Limited

# FDA Approves KLM Laboratories' Generic Mesalamine Rectal Formulation KLM Laboratories Private Limited received FDA approval for its generic mesalamine rectal formulation (ANDA22…

FDA ScieGen Mar 31 — 0.00

FDA Approves OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE — ScieGen Pharmaceuticals Inc

# FDA Approves Generic Olmesartan Medoxomil and Hydrochlorothiazide Combination ScieGen Pharmaceuticals Inc received FDA approval for a generic version of olmesartan medoxomil and…

FDA Baxter Mar 30 — 0.00

FDA Approves EPINEPHRINE — Baxter Healthcare Corporation

# FDA Approves Baxter Healthcare's Intramuscular Epinephrine Formulation Baxter Healthcare Corporation received FDA approval for its intramuscular epinephrine formulation (NDA2206…

FDA SAGENT Mar 26 — 0.00

FDA Approves Unknown Drug — SAGENT

On March 26, 2026, SAGENT received FDA approval for a new drug, signaling a strategic entry into the market with potential to compete against existing products. The approval is poi…

FDA Denali Mar 24 — 0.00

FDA Approves AVLAYAH — Denali Therapeutics Inc.

# FDA Approves Denali Therapeutics' AVLAYAH, Expanding Its Neurology Portfolio Denali Therapeutics Inc. received FDA approval for AVLAYAH (tividenofusp alfa-eknm), an intravenous …

FDA Macleods Mar 23 — 0.00

FDA Approves MEXILETINE HYDROCHLORIDE — Macleods Pharmaceuticals Limited

# FDA Approves Generic Mexiletine Hydrochloride from Macleods Pharmaceuticals Macleods Pharmaceuticals Limited has received FDA approval for its generic mexiletine hydrochloride o…

FDA Aurobindo Mar 23 — 0.00

FDA Approves CEFIXIME — Aurobindo Pharma Limited

# FDA Approves Aurobindo Pharma's Generic Cefixime Oral Formulation The U.S. FDA has approved Aurobindo Pharma Limited's abbreviated new drug application (ANDA217607) for generic …

FDA Advagen Mar 20 — 0.00

FDA Approves ATOMOXETINE HYDROCHLORIDE — Advagen Pharma Ltd.

# FDA Approves Advagen Pharma's Atomoxetine Hydrochloride for Oral Administration Advagen Pharma Ltd. has received FDA approval for its atomoxetine hydrochloride oral formulation …

FDA FRESENIUS Mar 19 — 0.00

FDA Approves Unknown Drug — FRESENIUS KABI USA

# FDA Approves Generic Drug for Fresenius Kabi USA Fresenius Kabi USA received FDA approval for a generic drug formulation under ANDA219991, expanding the company's portfolio in t…

FDA ACTAVIS Mar 19 — 0.00

FDA Approves Unknown Drug — ACTAVIS LABS FL INC

# FDA Approves Generic Drug Application for Actavis Labs FL Inc Actavis Labs FL Inc received FDA approval for abbreviated new drug application (ANDA) 208959 on March 19, 2026, pos…

FDA Septodont, Mar 19 — 0.00

FDA Approves FLAVALTA — Septodont, Inc.

Septodont Inc. has received FDA approval for the Flavalta submucosal lidocaine and epinephrine system, a launch set for March 19, 2026, which is expected to provide a competitive a…

FDA GLENMARK Mar 16 — 0.00

FDA Approves FLUTICASONE PROPIONATE ALLERGY RELIEF — GLENMARK THERAPEUTICS INC., USA

# FDA Approves Glenmark Therapeutics' Generic Fluticasone Propionate Nasal Spray The FDA has approved Glenmark Therapeutics Inc.'s abbreviated new drug application for generic flu…